- Home
- RL vs BIIB Comparison
RL vs BIIB Comparison
Compare RL & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RL
- BIIB
- Stock Information
- Founded
- RL 1967
- BIIB 1978
- Country
- RL United States
- BIIB United States
- Employees
- RL N/A
- BIIB N/A
- Industry
- RL Apparel
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- RL Consumer Discretionary
- BIIB Health Care
- Exchange
- RL Nasdaq
- BIIB Nasdaq
- Market Cap
- RL 19.4B
- BIIB 18.7B
- IPO Year
- RL 1997
- BIIB 1991
- Fundamental
- Price
- RL $324.68
- BIIB $154.38
- Analyst Decision
- RL Strong Buy
- BIIB Buy
- Analyst Count
- RL 15
- BIIB 24
- Target Price
- RL $349.27
- BIIB $174.62
- AVG Volume (30 Days)
- RL 607.3K
- BIIB 1.6M
- Earning Date
- RL 11-06-2025
- BIIB 10-30-2025
- Dividend Yield
- RL 1.12%
- BIIB N/A
- EPS Growth
- RL 28.75
- BIIB N/A
- EPS
- RL 13.54
- BIIB 10.97
- Revenue
- RL $7,570,600,000.00
- BIIB $10,065,900,000.00
- Revenue This Year
- RL $10.57
- BIIB $2.97
- Revenue Next Year
- RL $4.87
- BIIB N/A
- P/E Ratio
- RL $23.99
- BIIB $14.17
- Revenue Growth
- RL 12.32
- BIIB 4.77
- 52 Week Low
- RL $176.61
- BIIB $110.04
- 52 Week High
- RL $341.90
- BIIB $176.95
- Technical
- Relative Strength Index (RSI)
- RL 53.69
- BIIB 59.29
- Support Level
- RL $306.55
- BIIB $148.90
- Resistance Level
- RL $337.56
- BIIB $157.79
- Average True Range (ATR)
- RL 9.77
- BIIB 4.78
- MACD
- RL -1.83
- BIIB 0.43
- Stochastic Oscillator
- RL 53.69
- BIIB 82.77
About RL Ralph Lauren Corporation
Founded by designer Ralph Lauren (current executive chairman and chief creative officer) in 1967 in New York City, Ralph Lauren Corp. designs, markets, and distributes lifestyle merchandise in North America, Europe, and Asia. Best known for its iconic polo shirts, its products also include other types of apparel, footwear, eyewear, jewelry, handbags, home goods, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, and Lauren Ralph Lauren. Distribution channels for Ralph Lauren include wholesale (department stores and specialty stores), retail (company-owned retail stores and e-commerce), and licensing.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.